314 related articles for article (PubMed ID: 19549601)
1. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
Swedberg JE; Nigon LV; Reid JC; de Veer SJ; Walpole CM; Stephens CR; Walsh TP; Takayama TK; Hooper JD; Clements JA; Buckle AM; Harris JM
Chem Biol; 2009 Jun; 16(6):633-43. PubMed ID: 19549601
[TBL] [Abstract][Full Text] [Related]
2. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
Mize GJ; Wang W; Takayama TK
Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
[TBL] [Abstract][Full Text] [Related]
4. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).
Ramsay AJ; Reid JC; Adams MN; Samaratunga H; Dong Y; Clements JA; Hooper JD
Biol Chem; 2008 Jun; 389(6):653-68. PubMed ID: 18627286
[TBL] [Abstract][Full Text] [Related]
5. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
6. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7.
Arama DP; Soualmia F; Lisowski V; Longevial JF; Bosc E; Maillard LT; Martinez J; Masurier N; El Amri C
Eur J Med Chem; 2015 Mar; 93():202-13. PubMed ID: 25682203
[TBL] [Abstract][Full Text] [Related]
7. Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development.
Caliendo G; Santagada V; Perissutti E; Severino B; Fiorino F; Frecentese F; Juliano L
J Med Chem; 2012 Aug; 55(15):6669-86. PubMed ID: 22607152
[No Abstract] [Full Text] [Related]
8. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer.
Hollenberg MD; Oikonomopoulou K; Hansen KK; Saifeddine M; Ramachandran R; Diamandis EP
Biol Chem; 2008 Jun; 389(6):643-51. PubMed ID: 18627296
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.
Ramsay AJ; Dong Y; Hunt ML; Linn M; Samaratunga H; Clements JA; Hooper JD
J Biol Chem; 2008 May; 283(18):12293-304. PubMed ID: 18308730
[TBL] [Abstract][Full Text] [Related]
10. Development of plasma kallikrein selective inhibitors.
Okada Y; Tsuda Y; Tada M; Wanaka K; Hijikata-Okunomiya A; Okamoto U; Okamoto S
Biopolymers; 1999; 51(1):41-50. PubMed ID: 10380351
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ
Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585
[TBL] [Abstract][Full Text] [Related]
12. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin.
Markland W; Ley AC; Ladner RC
Biochemistry; 1996 Jun; 35(24):8058-67. PubMed ID: 8672510
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12).
Memari N; Jiang W; Diamandis EP; Luo LY
Biol Chem; 2007 Apr; 388(4):427-35. PubMed ID: 17391064
[TBL] [Abstract][Full Text] [Related]
14. KLK4 Inhibition by Cyclic and Acyclic Peptides: Structural and Dynamical Insights into Standard-Mechanism Protease Inhibitors.
Riley BT; Ilyichova O; de Veer SJ; Swedberg JE; Wilson E; Hoke DE; Harris JM; Buckle AM
Biochemistry; 2019 May; 58(21):2524-2533. PubMed ID: 31058493
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6).
Fernández IS; Ständker L; Mägert HJ; Forssmann WG; Giménez-Gallego G; Romero A
J Mol Biol; 2008 Apr; 377(5):1488-97. PubMed ID: 18329042
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation.
Bayés A; Tsetsenis T; Ventura S; Vendrell J; Aviles FX; Sotiropoulou G
Biol Chem; 2004 Jun; 385(6):517-24. PubMed ID: 15255184
[TBL] [Abstract][Full Text] [Related]
17. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
Swedberg JE; de Veer SJ; Harris JM
Biol Chem; 2010 Apr; 391(4):357-74. PubMed ID: 20180638
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors of plasma kallikrein.
Young WB; Rai R; Shrader WD; Burgess-Henry J; Hu H; Elrod KC; Sprengeler PA; Katz BA; Sukbuntherng J; Mordenti J
Bioorg Med Chem Lett; 2006 Apr; 16(7):2034-6. PubMed ID: 16413183
[TBL] [Abstract][Full Text] [Related]
19. Characterization of mouse glandular kallikrein 24 expressed in testicular Leydig cells.
Matsui H; Takano N; Takahashi T
Int J Biochem Cell Biol; 2005 Nov; 37(11):2333-43. PubMed ID: 15985384
[TBL] [Abstract][Full Text] [Related]
20. Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.
Seiz L; Kotzsch M; Grebenchtchikov NI; Geurts-Moespot AJ; Fuessel S; Goettig P; Gkazepis A; Wirth MP; Schmitt M; Lossnitzer A; Sweep FC; Magdolen V
Biol Chem; 2010 Apr; 391(4):391-401. PubMed ID: 20180634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
